Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide

Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the...

Descripción completa

Detalles Bibliográficos
Autores principales: Abeer, Muhammad Mustafa, Meka, Anand Kumar, Pujara, Naisarg, Kumeria, Tushar, Strounina, Ekaterina, Nunes, Rute, Costa, Ana, Sarmento, Bruno, Hasnain, Sumaira Z., Ross, Benjamin P., Popat, Amirali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723263/
https://www.ncbi.nlm.nih.gov/pubmed/31430872
http://dx.doi.org/10.3390/pharmaceutics11080418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723263/
https://www.ncbi.nlm.nih.gov/pubmed/31430872
http://dx.doi.org/10.3390/pharmaceutics11080418

Ejemplares similares